We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

104 hedge funds and large institutions have $74.3M invested in Endocyte, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

6% more funds holding

Funds holding: 98104 (+6)

2% less call options, than puts

Call options by funds: $661K | Put options by funds: $672K

9% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 32

13% less capital invested

Capital invested by funds: $85.5M → $74.3M (-$11.2M)

Holders
104
Holders Change
+6
Holders Change %
+6.12%
% of All Funds
2.9%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
15
Increased
29
Reduced
32
Closed
9
Calls
$661K
Puts
$672K
Net Calls
-$11K
Net Calls Change
+$331K

ECYT Hedge Fund Activity: Q3 2015 in Review

104 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q3 2015, worth a combined $74.3M — down 13% from $85.5M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ECYT positions and 9 closed out — a net gain of 6 holders — while 29 added to existing stakes and 32 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $7.1M. The largest seller was Numeric Investors, cutting an estimated $3.18M.

  • 104 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q3 2015, up from 98 in Q2 2015.
  • Funds reported $74.3M of Endocyte, Inc. Common Stock stock for Q3 2015, down 13% quarter-over-quarter.
  • 15 funds opened new Endocyte, Inc. Common Stock positions in Q3 2015 and 9 closed out, a net change of +6 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q3 2015 was Baker Bros. Advisors, an estimated $7.1M added.
  • The largest Endocyte, Inc. Common Stock seller in Q3 2015 was Numeric Investors, an estimated $3.18M sold.

Based on aggregated 13F filings for Q3 2015.